Author

S. Hamis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

G. Powathil· 2 shared A. McLaren· 1 shared C. J. Henderson· 1 shared C. R. Wolf· 1 shared D. Finkelshtein· 1 shared D. S. Tadele· 1 shared J. A. Agren· 1 shared J. G. Scott· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Powathil

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Simulations probe the role of space in the interplay between drug-sensitive and drug-resistant cancer cells

K. Pugh, R. D. Jones, G. Powathil, S. Hamis

This study uses mathematical models to show that spatial factors influence drug response and competition between drug-sensitive and drug-resistant cancer cells.

bioRxiv · Apr 29, 2024Cancer Biology

Spatial cumulant models enable spatially informed treatment strategies and analysis of local interactions in cancer systems

S. Hamis, P. Somervuo, J. A. Agren, D. S. Tadele, J. Kesseli, J. G. Scott, M. Nykter, P. Gerlee, D. Finkelshtein, O. Ovaskainen

This paper introduces spatial cumulant models to analyze and improve treatment strategies for cancer cell populations modeled as spatio-temporal point processes.

bioRxiv · May 7, 2022Cancer Biology

Quantifying ERK-activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling

S. Hamis, Y. Kapelyukh, A. McLaren, C. J. Henderson, C. R. Wolf, M. A. J. Chaplain

This study develops a mathematical model to quantify how dabrafenib and trametinib inhibit ERK-activity in BRAFV600E-mutant melanoma cells and identify mechanisms of drug resistance.

bioRxiv · Apr 20, 2021Cancer Biology

What does not kill a tumour may make it stronger: in silico Insights into Chemotherapeutic Drug Resistance

S. Hamis, P. Nithiarasu, G. Powathil

This study uses an in silico framework to analyze how chemotherapy induces drug resistance in tumors by simulating various resistant mechanisms and optimizing treatment strategies.

bioRxiv · Apr 13, 2018Cancer Biology